Apr 26, 2023 / 08:30PM GMT
Operator
Hello, and welcome to the Alnylam Pharmaceuticals conference call to discuss interim results from the Phase I study of ALN-APP Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to the company. Please go ahead.
Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. - Senior VP of IR & Corporate Communications
Good afternoon. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today on the phone are Yvonne Greenstreet, our Chief Executive Officer; Pushkal Garg, our Chief Medical Officer; and Akshay Vaishnaw, our President. Also in the room and available for Q&A is Kevin Fitzgerald, our Chief Scientific Officer. For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investors page of our website, alnylam.com/events. Now turning to today's call as outlined on Slide 2. Yvonne will provide some opening remarks,
Alnylam Pharmaceuticals Inc ALN-APP Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot